Intratumoral Combinatorial Administration of CD1c (BDCA-1)<sup>+</sup> Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

Intratumoral Combinatorial Administration of CD1c (BDCA-1)<sup>+</sup> Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in re-licensing antitumor cytotoxic T lymphocytes. IT injection of the IgG<sub>1</sub> monoclonal antibodies ipilimumab and avelumab may induce antibody-dependent cellular cytotoxicity, thereby enhancing the release of...

Full description

Bibliographic Details
Main Authors: Julia Katharina Schwarze, Gil Awada, Louise Cras, Jens Tijtgat, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Vaccines
Subjects:
cancer immunotherapy
dendritic cells
intratumoral
myeloid dendritic cells
conventional dendritic cells
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2076-393X/8/4/670

Similar Items

Similar Items